Novartis’ Fabhalta Gets FDA Approval for Rare Complement Blood Disorder
XTalks
DECEMBER 12, 2023
After receiving US Food and Drug Administration (FDA) approval for Fabhalta (iptacopan) last week for the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH), Novartis presented trial data yesterday showing the drug’s promise in another indication.
Let's personalize your content